Evidence map›Paper›PMID 35096555›Full record

ArticleFrontiers in oncology2021

Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma.

Fei Yang, Jun Yang, Wei Xiang, Bin-Yan Zhong, Wan-Ci Li, Jian Shen, Shuai Zhang, Yu Yin, Hong-Peng Sun, Wan-Sheng Wang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Fei YangDepartment of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Jun YangDepartment of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Wei XiangDepartment of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Bin-Yan ZhongDepartment of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Wan-Ci LiDepartment of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Jian ShenDepartment of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Shuai ZhangDepartment of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Yu YinDepartment of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Hong-Peng SunDepartment of Child Health, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, School of Public Health, Soochow University, Suzhou, China.
Wan-Sheng WangDepartment of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Xiao-Li ZhuDepartment of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo explore the safety and efficacy of transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) for the treatment of unresectable hepatocellular carcinoma (uHCC). MATERIALS AND

methodsFrom August 2019 to July 2020, patients who received TACE combined with ICIs and TKIs were retrospectively analyzed. Treatment-related adverse events (AEs) were recorded. The Kaplan-Meier method was used to estimate time to progression (TTP) and progression-free survival (PFS).

resultsIn total, 31 patients with uHCC were included. Eleven patients were classified as BCLC-C. Nineteen patients had multiple lesions, and the cumulative targeted lesions were 69 mm (range, 21-170 mm) according to mRECIST. Twenty-nine (93%) patients experienced at least one AE during the treatment. Four (12.9%) patients developed AEs of higher grade (grade≥3). The objective response rate (ORR) and disease control rate (DCR) were 64.5% and 77.4%, respectively. The median time to response was 7 weeks (range, 4-30 w), and the duration of response was 17.5 weeks (range, 2-46 w). From the first ICIs, TTP and PFS were 6.5 months (95% CI, 3.5-11) and 8.5 months (95% CI, 3.5-NE), respectively.

conclusionsTACE combined with ICIs and TKIs shows an acceptable safety profile and considerable efficacy in patients with HCC.

Indexed as

hepatocellular carcinomaimmune checkpoint inhibitorsimmunotherapyTACEtargeted therapytyrosine kinase inhibitors

Identifiers

PMID35096555
PMCPMC8792047

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.